Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6
Autore:
Lee, TM; Su, SF; Hwang, JJ; Tseng, CD; Chen, MF; Lee, YT; Wang, SS;
Indirizzi:
Natl Taiwan Univ Hosp, Dept Surg, Cardiol Sect, Taipei 100, Taiwan Natl Taiwan Univ Hosp Taipei Taiwan 100 Cardiol Sect, Taipei 100, Taiwan Natl Taiwan Univ Hosp, Dept Internal Med, Cardiol Sect, Taipei 10002, Taiwan Natl Taiwan Univ Hosp Taipei Taiwan 10002 iol Sect, Taipei 10002, Taiwan Natl Cheng Kung Univ, Coll Med, Dept Clin Pharm, Tainan 70101, Taiwan NatlCheng Kung Univ Tainan Taiwan 70101 lin Pharm, Tainan 70101, Taiwan
Titolo Testata:
ATHEROSCLEROSIS
fascicolo: 2, volume: 158, anno: 2001,
pagine: 471 - 476
SICI:
0021-9150(200110)158:2<471:DLEOCA>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERIPHERAL ARTERIAL-DISEASE; KAPPA-B; CHOLESTEROL; CELLS; GENE; MICE; RISK;
Keywords:
cilostazol; interleukin-6; intermittent claudication; lipid; pentoxifylline; peripheral vascular disease; phosphodiesterase inhibitor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Wang, SS Natl Taiwan Univ Hosp, Dept Surg, Cardiol Sect, Taipei 100, Taiwan Natl Taiwan Univ Hosp Taipei Taiwan 100 ect, Taipei 100, Taiwan
Citazione:
T.M. Lee et al., "Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6", ATHEROSCLER, 158(2), 2001, pp. 471-476

Abstract

Cilostazol, a novel oral phosphodiesterase inhibitor, has shown consistentimprovement in exercise tolerance in patients with intermittent claudication. (IC). In addition to this effect, cilostazol has previously been shown.to have beneficial effects on the dyslipidemia, i.e., combination of high triglycerides with low high-density-lipoprotein cholesterol (HDL-Q levels. Interluekin-6 (IL-6) suppresses the activity of lipoprotein lipase, which modulates the metabolism of triglycerides and HDL-C. To determine whether a reduction of IL-6 contributes to the improvement of lipid profiles, we prospectively investigated the effect of cilostazol (n = 16, 100 mg, twice daily) on the changes of lipid profiles and on the association with the changesof IL-6 compared with those of pentoxifylline (n = 16, 400 mg, bid) in patients with IC. After eight weeks of administration of cilostazol to patients with IC, walking distances were increased, associated with a 29% decreasein plasma triglycerides and a 13% increase in HDL-C. No significant changes of lipid profiles in the pentoxifylline and placebo groups were observed although a similar improvement in walking distances was achieved in the pentoxifylline group. IL-6 levels were significantly reduced in patients receiving cilostazol as compared with those receiving placebo or pentoxifylline. The cilostazol-induced changes in the IL-6 were positively related to those of triglycerides in the cilostazol group (r = 0.63, P < 0.05) and negatively related to those of HDL-C (r = - 0.55, P < 0.05). These findings suggest that in addition to consistent improvement of exercise tolerance, cilostazol may improve lipid profiles by reducing IL-6 release. However, pentoxifylline did not affect lipid profiles although a similar improvement of maximal walking distance (MWD) was achieved. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 19:19:03